ALT/AST levels rapidly returned to baseline values after discontinuation of treatment; two participants who did not immediately discontinue therapy demonstrated a clear trend toward normalization of ALT/AST levels while maintained on study drug.
← all excerpts
A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
1
—
—